TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06768203

Intervention type: OTHER
Intervention: umbilical vein catheterization
Description: In our NICU, UVC placement is a sterile bedside procedure carried out by pediatric residents, neonatology fellows, and neonatology specialists, using polyurethane, single-lumen catheters sized according to the infant's weight: 3.5 Fr for those under 1500 g and 5 Fr for those over 1500 g. Catheter placement is performed using the Modified Shukla-Ferrara Formula

Intervention type: OTHER
Intervention: Control
Description: No umbilical vein catheter was inserted in these infants.
Study: NCT06767826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salutogenesis Models
Description: On the basis of the Salutogenesis Model, this study is based on the development of individuals' internal and external resources for game addictions and strengthening their sense of integrity. It has been determined that digital game addiction and problematic internet use in adolescents form the basis of seven problems. These problems have been identified as mental health, vision, pain, sleep and rest patterns, nutrition, social contact and physical activity. Encouraging behavioral changes regarding internet use and teaching adolescents how to deal with these problems becomes a necessity in today's technology. In the literature, counseling has been provided for families and adolescents to prevent digital game addiction in adolescents.
Study: NCT06769763

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My Journey with MS application
Description: This is an Arabic application for MS patients that provides them with information about self-care like nutrition, exercise, mental health, and self-management, in addition to other features like symptom tracking and medication reminders.
Study: NCT06768125

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: 95% PGTVp: 33 Gy in 3.3 Gy per session for 10 sessions, and 95% PTV1: 25 Gy in 1.5 Gy per session for 10 sessions, with an interval of 1-2 weeks, for a total of 2 cycles.
Study: NCT06768736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalised early warning system
Description: Early warning system personalised forecasting messages
Study: NCT06769659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPT 2042
Description: NPT 2042 is a new drug being developed as an anti-seizure treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPT 2042
Description: NPT 2042 is a new drug being developed as an anti-seizure treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT06768515

Intervention type: OTHER
Intervention: No interventtion
Description: to enhance the understanding of the factors associated with the number of organs retrieved from patients admitted to the ICU for organ donation
Study: NCT05445544

Intervention type: OTHER
Intervention: Observational studies, The diagnosis was preeclampsia
Description: Observational studies, The diagnosis was preeclampsia
Study: NCT04748042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone 1000 mg by mouth per day for approximately 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg by mouth per day for approximately 6 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
Study: NCT05578625

Intervention type: OTHER
Intervention: plasma circulation DNA methylation sequencing
Description: 10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.
Study: NCT05501496

Intervention type: PROCEDURE
Group type: OTHER
Intervention: casting
Description: casting with long leg cast
Study: NCT05928429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA
Description: Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
Study: NCT06244056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block
Description: A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block
Description: A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.
Study: NCT05001516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.
Study: NCT05819814

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Disclosure of high polygenic risk result for coronary artery disease
Description: The disclosure of a high polygenic risk result for coronary artery disease involves a clinical report coupled with a virtual meeting with a genetic counselor.
Study: NCT05899465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
Study: NCT05238870

Intervention type: OTHER
Intervention: Interviews for the needs analysis. No intervention.
Description: To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.

Intervention type: OTHER
Intervention: Interviews for the needs analysis. No intervention.
Description: To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.

Intervention type: OTHER
Intervention: Interviews for the needs analysis. No intervention.
Description: To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.
Study: NCT05555524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby oil
Description: Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks
Study: NCT05085821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEART
Description: In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEART
Description: In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEART
Description: In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEART
Description: In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
Study: NCT05043701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized drug combination
Description: A personalized drug combination will be prescribed to each patient based on the functional drug screen
Study: NCT05971901

Intervention type: DIAGNOSTIC_TEST
Intervention: BV
Description: The use of the BV test, ordered at the discretion of the treating physician
Study: NCT04705064

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of postoperative acute kidney injury using an artificial intelligence
Description: The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
Study: NCT05502614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Transcutaneous stimulation of the dorsal genital nerve using the Innocon Medical UCon device to provide on demand relief of bladder spasms
Study: NCT05568524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFRT
Description: Low-load (30% 1RM) resistance exercise with blood flow restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Moderate-to-high load (60%-80% 1RM) resistance exercise
Study: NCT06382038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile venous thromboembolism application (mVTEA)
Description: mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
Study: NCT06096324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Job announcements plus educational sessions, mentoring, a micro-grant, and behavioral economic text messages
Description: Participants will receive job announcements plus educational sessions, mentoring, a micro-grant, and behavioral economic text messages.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Job announcements
Description: Participants will receive job announcements only.
Study: NCT04962399

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme linked immunosorbent assay
Description: Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme linked immunosorbent assay
Description: Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme linked immunosorbent assay
Description: Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.
Study: NCT05502419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural slump mobilization
Description: Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
Study: NCT05842213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT05 (proposed biosimilar to golimumab)
Description: AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVT05 (proposed biosimilar to golimumab)
Description: AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simponi (Golimumab)
Description: Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection
Study: NCT06075797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PediQUEST ResPOND
Description: PPC teams will have access to feedback reports and the PQ-ResPOND checklist (standardized framework to diagnosis and treatment of recurrent pain behaviors in children with severe neurologic impairment).~Integration of the PPC team into care will be achieved through (i) initial consultation (goals: identify treatment goals, and address recurrent pain), and (ii) follow-up: the team will contact or visit the family in response to feedback reports or for treatment monitoring purposes.
Study: NCT05891626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention
Description: An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~1. missed opportunities and doubts/hesitancy about immunization as a whole;~2. specific questions with regard to specific vaccines;~3. health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~4. challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level.
Study: NCT06377930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAP-219
Description: RAP-219 oral tablet
Study: NCT06183476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amplify-RHYTHM
Description: Amplify-RHYTHM will have two main components: 1) timed light exposure (increase light in the morning, blue light reduction in the evening and eye masks at night), 2) weekly remote coaching session by psychologist to optimize circadian and sleep behaviors
Study: NCT06452147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve block+standard anesthesia
Description: 1. Receive nerve block as soon as possible after randomization;~2. Ultrasound-guided nerve block is recommended, with the iliacfascia block recommended as the blocking site;~3. It is recommended to use 1.33% bupivacaine liposome (long-acting), and the maximum dose should not exceed 133mg; or regular local anesthetic (bupivacaine or ropivacaine, etc.) with electronic analgesic pumping infusion; or multiple single injections of regular local anesthetics should be used to maintain the continuity of nerve block effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine+standard anesthesia
Description: 1. Subjects randomly assigned to Lidocaine Group (Group L) will be given ECG monitoring, oxygen saturation monitoring, blood pressure monitoring and an open intravenous route on the morning of the surgery. It is recommended to start the infusion of Lidocaine as soon as possible in the ward.~2. It is recommended to use portable electronic infusion pump for drug delivery. The loading dose is 1mg/kg, and the maintenance dose range is 1\~2mg/kg/h. The specific dosage is determined by the anesthesiologist based on the patient's condition. The infusion ends when the patient leaves the Post-anesthesia care unit after surgery, and the infusion time and total amount should be recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: 1.33% bupivacaine liposome

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve block
Description: Ultrasound-guided nerve block
Study: NCT05989074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLEGRA TAVI System TF
Description: Patients receive ALLEGRA TAVI System TF. Patient will receive medication according to routine practice of the hospital

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ballon-expandable valve system
Description: Patients receive any kind of CE-marked balloon expandable valve system, used at the hospital. Patient will receive medication according to routine practice of the hospital.
Study: NCT06038058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRY812 for injection
Description: BRY812 for injection will be administered by intravenous drip, tentatively once per cycle spanning 3 weeks on D1 of each cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
Study: NCT06537011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: 1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery.
Study: NCT06525363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: chitosan nanoparticles 1%w/w will be formulated in form of spray for oral application twice daily
Study: NCT05093387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Transferrin Receptor-Targeted Liposomal p53 cDNA
Description: Given IV